Protein Biomarkers of Ovarian Cancer: the Forest and the Trees

Overview

Journal Future Oncol

Specialty Oncology

Date 2011 Dec 14

PMID 22149035

Citations 34

Authors

Brian M Nolen

Anna E Lokshin

Affiliations

Soon will be listed here.

Abstract

The goal of effective population-based screening for ovarian cancer remains elusive despite intense efforts aimed at improving upon biomarker and imaging modalities. While dozens of potential serum biomarkers for ovarian cancer have been identified in recent years, none have yet overcome the limitations that have hindered the clinical use of CA-125. Avenues of opportunity in biomarker development are emerging as investigators are beginning to appreciate the significance of remote, as well as local or regional, sources of biomarkers in the construction of diagnostic panels, as well as the importance of evaluating biomarkers in prediagnostic settings. As the list of candidate biomarkers of ovarian cancer continues to grow, refinements in the methods through which specific proteins are selected for further development as components of diagnostic panels are desperately sought. Such refinements must take into account both the bioinformatic and biological significance of each candidate. Approaches incorporating these considerations may potentially overcome the challenges to early detection posed by the histological heterogeneity of ovarian cancer. Here, we review the recent progress achieved in efforts to develop diagnostic biomarker panels for ovarian cancer and discuss the challenges that remain.

Citing Articles

Assessing the rates of false-positive ovarian cancer screenings and surgical interventions associated with screening tools: a systematic review.

Silverwood S, Backer G, Galloway A, Reid K, Jeter A, Harrison M BMJ Oncol. 2025; 3(1):e000404.

PMID: 39886168 PMC: 11261692. DOI: 10.1136/bmjonc-2024-000404.

Comparison of Human Epididymis Protein 4, Cancer Antigen 125, and Ultrasound Prediction Model in Differentiating Benign from Malignant Adnexal Masses.

Bahadur A, Bhattacharya N, Mundhra R, Khoiwal K, Chawla L, Singh R J Midlife Health. 2024; 14(3):176-183.

PMID: 38312761 PMC: 10836431. DOI: 10.4103/jmh.jmh_77_23.

Circulating Proteins as Diagnostic Markers in Gastric Cancer.

Repetto O, Vettori R, Steffan A, Cannizzaro R, De Re V Int J Mol Sci. 2023; 24(23).

PMID: 38069253 PMC: 10706891. DOI: 10.3390/ijms242316931.

A Novel Predictive Multi-Marker Test for the Pre-Surgical Identification of Ovarian Cancer.

Stephens A, Hobbs S, Kang S, Bilandzic M, Rainczuk A, Oehler M Cancers (Basel). 2023; 15(21).

PMID: 37958440 PMC: 10650329. DOI: 10.3390/cancers15215267.

Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer.

Niemira M, Erol A, Bielska A, Zeller A, Skwarska A, Chwialkowska K Sci Rep. 2023; 13(1):19287.

PMID: 37935712 PMC: 10630404. DOI: 10.1038/s41598-023-45317-7.

References

Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T . Histological classification of ovarian cancer. Med Electron Microsc. 2003; 36(1):9-17. DOI: 10.1007/s007950300002. View

Kurman R, Shih I . Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008; 27(2):151-60. PMC: 2794425. DOI: 10.1097/PGP.0b013e318161e4f5. View

Nasulewicz A, Mazur A, Opolski A . Role of copper in tumour angiogenesis--clinical implications. J Trace Elem Med Biol. 2004; 18(1):1-8. DOI: 10.1016/j.jtemb.2004.02.004. View

Su F, Lang J, Kumar A, Ng C, Hsieh B, Suchard M . Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights. 2009; 2:369-75. PMC: 2717832. View

Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T . Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(21):7677-82. PMC: 1140439. DOI: 10.1073/pnas.0502178102. View

Diamandis E, Van der Merwe D . Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res. 2005; 11(3):963-5. View

Zhang Z, Bast Jr R, Yu Y, Li J, Sokoll L, Rai A . Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004; 64(16):5882-90. DOI: 10.1158/0008-5472.CAN-04-0746. View

Menon U, Jacobs I . Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer. 2001; 11 Suppl 1:3-6. DOI: 10.1046/j.1525-1438.2001.11(suppl.1)sup1003.x. View

Greene M, Feng Z, Gail M . The importance of test positive predictive value in ovarian cancer screening. Clin Cancer Res. 2008; 14(22):7574. DOI: 10.1158/1078-0432.CCR-08-2232. View

10.

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

11.

Moshkovskii S, Serebryakova M, Kuteykin-Teplyakov K, Tikhonova O, Goufman E, Zgoda V . Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics. 2005; 5(14):3790-7. DOI: 10.1002/pmic.200401205. View

12.

Ceciliani F, Giordano A, Spagnolo V . The systemic reaction during inflammation: the acute-phase proteins. Protein Pept Lett. 2002; 9(3):211-23. DOI: 10.2174/0929866023408779. View

13.

Clarke-Pearson D . Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009; 361(2):170-7. DOI: 10.1056/NEJMcp0901926. View

14.

Skates S, Singer D . Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol. 1991; 44(4-5):365-80. DOI: 10.1016/0895-4356(91)90075-k. View

15.

Anderson G, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe J . Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010; 102(1):26-38. PMC: 2802285. DOI: 10.1093/jnci/djp438. View

16.

Dupont J, Tanwar M, Thaler H, Fleisher M, Kauff N, Hensley M . Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. 2004; 22(16):3330-9. DOI: 10.1200/JCO.2004.09.112. View

17.

Lin B, White J, Wu J, Lele S, Old L, Hood L . Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin Appl. 2010; 3(7):853-861. PMC: 2886282. DOI: 10.1002/prca.200800141. View

18.

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A . Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10(4):327-40. DOI: 10.1016/S1470-2045(09)70026-9. View

19.

Castracane V, Gimpel T, GOLDZIEHER J . Diagnosis of menopause: ratios of FSH/LH?. Fertil Steril. 1996; 66(5):866. DOI: 10.1016/s0015-0282(16)58658-0. View

20.

Andersen T, Curatolo L, REICHERT Jr L . Follitropin binding to receptors in testis: studies on the reversibility and thermodynamics of the reaction. Mol Cell Endocrinol. 1983; 33(1):37-52. DOI: 10.1016/0303-7207(83)90055-2. View